» Articles » PMID: 27657132

The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2016 Sep 23
PMID 27657132
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Telomeres are responsible for protecting chromosome ends in order to prevent the loss of coding DNA. Their maintenance is required for achieving immortality by neoplastic cells and can occur by upregulation of the telomerase enzyme or through a homologous recombination-associated process, the alternative lengthening of telomeres (ALT). The precise mechanisms that govern the activation of ALT or telomerase in tumor cells are not fully understood, although cellular origin may favor one of the other mechanisms that have been found thus far in mutual exclusivity. Specific mutational events influence ALT activation and maintenance: a unifying frequent feature of tumors that acquire this phenotype are the recurrent mutations of the Alpha Thalassemia/Mental Retardation Syndrome X-Linked (ATRX) or Death-Domain Associated Protein (DAXX) genes. This review summarizes the established criteria about this phenotype: its prevalence, theoretical molecular mechanisms and relation with ATRX, DAXX and other proteins (directly or indirectly interacting and resulting in the ALT phenotype).

Citing Articles

Mutant ATRX: pathogenesis of ATRX syndrome and cancer.

Yuan K, Tang Y, Ding Z, Peng L, Zeng J, Wu H Front Mol Biosci. 2024; 11:1434398.

PMID: 39479502 PMC: 11521912. DOI: 10.3389/fmolb.2024.1434398.


LAP2α orchestrates alternative lengthening of telomeres suppression through telomeric heterochromatin regulation with HDAC1: unveiling a potential therapeutic target.

Wang B, Kou H, Wang Y, Zhang Q, Jiang D, Wang J Cell Death Dis. 2024; 15(10):761.

PMID: 39426946 PMC: 11490576. DOI: 10.1038/s41419-024-07116-4.


The Future of Targeted Therapy for Leiomyosarcoma.

Denu R, Dann A, Keung E, Nakazawa M, Nassif Haddad E Cancers (Basel). 2024; 16(5).

PMID: 38473300 PMC: 10930698. DOI: 10.3390/cancers16050938.


Telomere Maintenance Mechanisms in a Cohort of High-Risk Neuroblastoma Tumors and Its Relation to Genomic Variants in the and Genes.

Djos A, Thombare K, Vaid R, Gaarder J, Umapathy G, Reinsbach S Cancers (Basel). 2023; 15(24).

PMID: 38136279 PMC: 10741428. DOI: 10.3390/cancers15245732.


Next-Generation Sequencing Analysis of 3 Uterine Adenosarcomas with Heterogeneously Differentiated Genomic Mutations.

Li Y, Meng X, Luo Y, Huang X, Luo S, Wang J Int J Anal Chem. 2023; 2023:7436368.

PMID: 37810911 PMC: 10555499. DOI: 10.1155/2023/7436368.


References
1.
Henson J, Hannay J, McCarthy S, Royds J, Yeager T, Robinson R . A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res. 2005; 11(1):217-25. View

2.
Venturini L, Daidone M, Motta R, Cimino-Reale G, Hoare S, Gronchi A . Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. Neuro Oncol. 2012; 14(6):736-44. PMC: 3367852. DOI: 10.1093/neuonc/nos083. View

3.
Poole L, Zhao R, Glick G, Lovejoy C, Eischen C, Cortez D . SMARCAL1 maintains telomere integrity during DNA replication. Proc Natl Acad Sci U S A. 2015; 112(48):14864-9. PMC: 4672769. DOI: 10.1073/pnas.1510750112. View

4.
Stavropoulos D, Bradshaw P, Li X, Pasic I, Truong K, Ikura M . The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis. Hum Mol Genet. 2002; 11(25):3135-44. DOI: 10.1093/hmg/11.25.3135. View

5.
Cesare A, Griffith J . Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol. 2004; 24(22):9948-57. PMC: 525488. DOI: 10.1128/MCB.24.22.9948-9957.2004. View